Refractory Palmoplantar Pustular Psoriasis Treated With High-Dose Ustekinumab After Initial Failure.


Journal

Journal of cutaneous medicine and surgery
ISSN: 1615-7109
Titre abrégé: J Cutan Med Surg
Pays: United States
ID NLM: 9614685

Informations de publication

Date de publication:
Historique:
pubmed: 25 8 2018
medline: 25 6 2019
entrez: 25 8 2018
Statut: ppublish

Résumé

Palmoplantar pustular psoriasis (PPPP) is a form of psoriasis that can be difficult to treat. We describe a case of PPPP in a patient who failed multiple therapies, including ustekinumab. The patient subsequently developed inflammatory bowel disease (IBD), and restarting ustekinumab, with inflammatory bowel disease loading doses and optimization, resulted in complete resolution of her PPPP. This success occurred after she developed tachyphylaxis against the usual dosing of ustekinumab, demonstrating a recapture of the treatment response.

Identifiants

pubmed: 30141337
doi: 10.1177/1203475418795823
doi:

Substances chimiques

Dermatologic Agents 0
Ustekinumab FU77B4U5Z0

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

102-104

Auteurs

Michal Bohdanowicz (M)

1 Division of Dermatology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada.

Dusan Sajic (D)

2 Guelph Dermatology Research, Guelph, ON, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH